The following is a summary of “Feasibility of trancutaneous auricular vagus nerve stimulation in Black and Hispanic/Latino people with peripheral neuropathy,” published in the January 2025 issue of ...

The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...

Diabetic neuropathy is a common and serious complication of diabetes that affects the nerves, often in the hands, feet, and legs. It can cause symptoms like tingling, numbness, burning pain ...

Following the onset of nonarteritic anterior ischemic optic neuropathy, regular stroke workup may be necessary.

Patients with evidence of vitamin B 12 deficiency or diabetes were also excluded ... was not significantly different from the neuropathy in patients with non-alcohol-related cirrhosis.

GP Dr Roger Henderson provides an overview of the chronic complications of diabetes and the key preventive measures ...

The FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.

The US Food and Drug Administration (FDA) announced its approval of a non-opioid treatment for moderate–severe acute chronic ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

The FDA approves suzetrigine, a non-opioid pain medication, offering a safer alternative to opioids for pain management, ...